Sign In
Buy SNOA
$1.14
-0.0200 (-1.72%)
At Close: Jun 23, 2026
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores
07:30am, Thursday, 09'th May 2024
BOULDER, CO / ACCESSWIRE / May 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous ac
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
07:30am, Tuesday, 09'th Apr 2024
BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous
BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
04:01pm, Thursday, 28'th Mar 2024
BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
04:01pm, Thursday, 28'th Mar 2024
BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
07:30am, Wednesday, 27'th Mar 2024
BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
04:10pm, Thursday, 08'th Feb 2024
Revenues increased 7% compared to quarter from prior year and 15% from prior quarter Improvement in gross margin for quarter of 19% compared to prior year Improvement in net loss for quarter of $1.0 m
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
07:30am, Tuesday, 23'rd Jan 2024
BOULDER, CO / ACCESSWIRE / January 23, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochloro
EMERYVILLE, Calif. & BOULDER, Colo.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and m
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
04:10pm, Monday, 13'th Nov 2023
Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024 Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period
BOULDER, CO / ACCESSWIRE / November 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochloro
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
09:10am, Thursday, 26'th Oct 2023
BOULDER, CO / ACCESSWIRE / October 26, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochloro
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
07:30am, Tuesday, 15'th Aug 2023
BOULDER, CO / ACCESSWIRE / August 15, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorou
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results
04:15pm, Thursday, 10'th Aug 2023
Revenue increased 6% in the first fiscal quarter compared to the same period last year, excluding a one-time event last year Margins remained consistent year over year in an inflationary period, exclu
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board
07:30am, Thursday, 03'rd Aug 2023
BOULDER, CO / ACCESSWIRE / August 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous
